← Leaderboards
Lei Jin
University Of Florida
$4,251,314
Attributed
$4,251,314
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $527.5K · FY2014–24$1M$750K$500K$250K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$4,251,314 · 5
AHRQ$0 · 1
By mechanism
R01$3,092,581 · 2
R21$828,833 · 2
R56$329,900 · 1
R36$0 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Florida
Same institution · by research overlap
- John W Sleasman$11,039,991
- Nadeem Khan$2,271,953
Others in their field
Top investigators on “Production”
- Eric S Lander · Whitehead Institute For Biomedical Res$568,626,051
- Bambra Strokes · Ppd Development Lp$526,656,217
- Richard A Gibbs · Baylor College Of Medicine$521,766,399
- Tracy L Nolen · Research Triangle Institute$451,761,218
- Sonia M Thomas · Research Triangle Institute$451,761,218
- David Heimbrook · Leidos Biomedical Research, Inc.$332,994,970
Research focus
ProductionMediatingIn VivoInfectionCellsSignal TransductionResponseLungImmune ResponseDendritic CellsInterferonsImmunogenicStreptococcus PneumoniaeTnfrsf1b GeneReceptorImmunityAdjuvantMucosal VaccineReportingExhibitsBaseCytokineMucosal ImmunityVaccine Adjuvant
Grant awards (16)
Lung IDO-1+ TNFR2+ cDC2 subset in control of lung mucosal tolerance: Mechanism and Application$424,641
R01 · FY2024 · HL · contact PI
Lung IDO-1+ TNFR2+ cDC2 subset in control of lung mucosal tolerance: Mechanism and Application$441,533
R01 · FY2023 · HL · contact PI
Lung IDO-1+ TNFR2+ cDC2 subset in control of lung mucosal tolerance: Mechanism and Application$449,524
R01 · FY2022 · HL · contact PI
Lung IDO-1+ TNFR2+ cDC2 subset in control of lung mucosal tolerance: Mechanism and Application$457,280
R01 · FY2021 · HL · contact PI
Mechanisms of STING-Mediated Mucosal Vaccine Adjuvant Activity of Cyclic di-GMP$298,442
R01 · FY2019 · AI · contact PI
Mechanisms of STING-dependent IFNgamma production during pulmonary pneumococcal infection$189,067
R21 · FY2019 · AI · contact PI
Mechanisms of STING-Mediated Mucosal Vaccine Adjuvant Activity of Cyclic di-GMP$298,516
R01 · FY2018 · AI · contact PI
Mechanisms of STING-dependent IFNgamma production during pulmonary pneumococcal infection$227,266
R21 · FY2018 · AI · contact PI
Mechanisms of STING-Mediated Mucosal Vaccine Adjuvant Activity of Cyclic di-GMP$298,587
R01 · FY2017 · AI · contact PI
Impact of Human STING Variants on Pneumococcal Vaccine Effectiveness$187,500
R21 · FY2017 · AI · contact PI
Mechanisms of STING-Mediated Mucosal Vaccine Adjuvant Activity of Cyclic di-GMP$239,308
R01 · FY2016 · AI · contact PI
Impact of Human STING Variants on Pneumococcal Vaccine Effectiveness$225,000
R21 · FY2016 · AI · contact PI
Mechanisms of STING-Mediated Mucosal Vaccine Adjuvant Activity of Cyclic di-GMP$63,221
R01 · FY2016 · AI · contact PI
Mechanisms of STING-Mediated Mucosal Vaccine Adjuvant Activity of Cyclic di-GMP$121,529
R01 · FY2015 · AI · contact PI
Mechanisms of STING-Mediated Mucosal Vaccine Adjuvant Activity of Cyclic di-GMP$329,900
R56 · FY2014 · AI · contact PI
Professionalism &Rationalization of Clinical Processes$0
R36 · FY2004 · HS